Investment
Features
FeesSafety
Academy
More
Pluang+

Stocks surge on acquisition news, speculative trading, and defense tech expansion

Market News
21 Jul 2026
Danny Green
View Source
Bullish
pluang ai news

Stocks saw notable gains driven by specific events: Cynata Therapeutics surged over 800% due to speculative trading without known corporate news; Utz Brands jumped nearly 89% following a $14.25 per share acquisition offer now under shareholder fairness review; Defense Technologies International rose 54% after expanding its defense tech into industrial markets. Leveraged ETFs linked to Nebius Group also gained strongly, reflecting positive momentum. These moves highlight how acquisitions, market expansion, and speculation can sharply influence daily stock performance.

More News

BTIG starts Philip Morris International with a Buy rating, expecting strong Q2 earnings and 3.05% dividend yield.

BTIG starts Philip Morris International with a Buy rating, expecting strong Q2 earnings and 3.05% dividend yield.

Analyst firm BTIG initiated a Buy rating on Philip Morris International, with the stock trading at $188.04. They project strong Q2 earnings of $2.05 per share and revenue growth to $10.64 billion, up from last year. The company also offers an attract...

Analyst Insights
Bullish
22 minutes ago
City Holding Co director buys 110 shares amid 11.27% YTD stock gain and steady dividends.

City Holding Co director buys 110 shares amid 11.27% YTD stock gain and steady dividends.

A director of City Holding Co increased their stake by purchasing 110 shares at $134.55 each, signaling confidence in the company. The stock has risen 11.27% year-to-date and is trading near its 52-week high, reflecting strong market performance. Cit...

Market News
Bullish
26 minutes ago
Chubb posts strong Q2 profit growth despite missing revenue targets, boosts dividends and share buyback.

Chubb posts strong Q2 profit growth despite missing revenue targets, boosts dividends and share buyback.

Chubb Limited reported Q2 core operating earnings per share of $7.26, beating estimates and marking an 18.2% increase year-over-year. However, consolidated net premiums written were $14.7 billion, below the expected $15.07 billion, though key segment...

Company Fundamentals
Bullish
29 minutes ago
Freeport-McMoRan Q2 2026 EPS expected up 11.1% on strong commodity prices despite revenue drop.

Freeport-McMoRan Q2 2026 EPS expected up 11.1% on strong commodity prices despite revenue drop.

Freeport-McMoRan is forecasted to report a Q2 2026 earnings per share (EPS) of $0.60, marking an 11.1% increase year-over-year, driven by strong commodity prices and demand for copper and gold. However, revenue is expected to decline by about 14.6% t...

Company Fundamentals
Bullish
36 minutes ago
Study confirms TLX591-Tx's safety and efficacy in advanced prostate cancer using PSMA-PET imaging for patient selection

Study confirms TLX591-Tx's safety and efficacy in advanced prostate cancer using PSMA-PET imaging for patient selection

Telix Pharmaceuticals published results from the ProstACT SELECT Phase 1 study showing that TLX591-Tx, a targeted radio antibody-drug conjugate therapy for advanced metastatic prostate cancer, is safe and effective when patients are selected using 68...

Company Fundamentals
Bullish
36 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App